Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML. Ladha A, Hui G, Cheung E, Berube C, et al. Leuk Lymphoma 2021;62:1510-1513.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ladha A, Hui G, Cheung E, Berube C, et al. Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML. Leuk Lymphoma 2021;62:1510-1513.
PMID: 33491527